I too hope the capital raise is attractively priced - and that it is a rights issue and not a placement. Need to lower my average buy-in price. Interesting the downgrade quoted EBITDA on this occasion. On review of past announcements guidance has been in regard to NPAT or NOPAT. Does this signal further impairments?
Ann: Cardno Provides Market Update and FY16 Guidance, page-9
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CDD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.010(4.17%) |
Mkt cap ! $13.28M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 25.0¢ | 20.5¢ | $26.36K | 110.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 33444 | 2 |
View Market Depth
| Last trade - 16.10pm 03/12/2024 (20 minute delay) ? |
| CDD (ASX) Chart |
